| Sep 3 |
Athira stock craters 72% on failed study for Alzheimer's drug
|
| Sep 3 |
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
|
| Aug 23 |
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
|
| Aug 7 |
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
|
| Aug 1 |
Athira Pharma GAAP EPS of -$0.70 beats by $0.04
|
| Aug 1 |
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
|
| Jun 12 |
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
|
| Jun 11 |
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
|
| Jun 3 |
We're A Little Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
|
